Individual sensitivity to recombinant human GH (r-hGH) is variable. Identification of genetic factors contributing to this variability has potential use for individualization of treatment. The objective of this study was to identify genetic markers and gene expression profiles associated with growth response on r-hGH therapy in treatment-naïve, prepubertal children with GH deficiency (GHD) or Turner syndrome (TS).
A prospective, multicenter, international, open-label pharmacogenomic study.
The associations of genotypes in 103 growth- and metabolism-related genes and baseline gene expression profiles with growth response to r-hGH (cm/year) over the first year were evaluated. Genotype associations were assessed with growth response as a continuous variable and as a categorical variable divided into quartiles.
Eleven genes in GHD and ten in TS, with two overlapping between conditions, were significantly associated with growth response either as a continuous variable (seven in GHD, two in TS) or as a categorical variable (four more in GHD, eight more in TS). For example, in GHD, GRB10 was associated with high response (≥Q3; P=0.0012), while SOS2 was associated with low response (≤Q1; P=0.006), while in TS, LHX4 was associated with high response (P=0.0003) and PTPN1 with low response (P=0.0037). Differences in expression were identified for one of the growth response-associated genes in GHD (AKT1) and for two in TS (KRAS and MYOD1).
Carriage of specific growth-related genetic markers is associated with growth response in GHD and TS. These findings indicate that pharmacogenomics could have a role in individualized management of childhood growth disorders.
Recombinant human GH (r-hGH) has proved to be a safe and effective treatment to increase growth rate and adult height across a range of growth disorders, and improve metabolic status in adult GH deficiency (GHD) (1, 2). There is, however, substantial interindividual variability in growth response to r-hGH (1), and health economic assessments have shown that variability in response to r-hGH is the most important factor determining the cost-effectiveness of treatment (3, 4, 5). Licensing authorities recognize that the posology of r-hGH needs to be individualized. Predicting growth response to r-hGH and personalizing dosing should, therefore, be a clinical priority. Beyond conventional growth predictors (e.g. age, weight and r-hGH dose at the start of treatment), the identification of genetic factors contributing to this variability can be used to promote individualization of GH (r-hGH) treatment for best patient outcome.
There are many pathways that regulate human growth, which include hormones, growth factors and cellular growth processes (6, 7). Polymorphisms that could alter the function of the genes in these pathways may affect growth response to r-hGH therapy. One such example is the GH receptor polymorphism, in which exon 3 is either present or absent. This has been shown to influence GH signal transduction in vitro and growth response to r-hGH in vivo (8): in meta-analyses, those who carry the exon 3 deletion grow more (by ∼1 cm in the first year) in response to r-hGH (9, 10). However, these meta-analyses demonstrate significant variation between reports on one condition, and between conditions. This highlights the limitations of studying the effect of a single gene on a complex trait, such as growth. Another approach to assessing r-hGH responsiveness, which uses a whole genome rather than candidate gene methodology, is to examine gene expression profiles. Using peripheral blood mononuclear cells (PBMCs) as the RNA source, this has generated data relevant to growth responses to r-hGH in children with GHD and Turner syndrome (TS), and in adults to detect r-hGH doping (11, 12). To date, a large-scale study in children with growth disorders has not been undertaken to address this important issue.
Pharmacogenomics has been successfully used in the field of cancer to identify benign vs malignant tumors and to quantify the risk of tumor recurrence (13, 14). Testing of specific genes is being used increasingly to predict response to drugs: the results of such tests can indicate whether a drug should not be used because of the risk of adverse events, or whether the dose to achieve a safe and efficacious outcome should be modified (15). In some instances, genetic testing has become part of the license requirements issued by regulatory authorities for use of a drug (15).
The PREDICT study (NCT00256126; Merck Serono S.A., Study 24531: A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children Treated with SAIZEN®) was a month-long trial to identify the most responsive serum biomarkers associated with growth response to r-hGH therapy. Two conditions, associated with significant short stature and well-characterized growth responses to r-hGH, were assessed, namely GHD and TS, which together account for ∼50% of r-hGH prescriptions.
The study presented here (NCT00699855; Merck Serono S.A., Study 28614: Observational Long-term Follow-up of the Phase IV Open-label Trial of Predictive Markers in Growth Hormone-Deficient and Turner Syndrome Pre-pubertal Children Treated with SAIZEN®) constitutes the first-year results following on from the PREDICT study, which uses a pharmacogenomic approach to evaluate the association of genetic polymorphisms in growth- and metabolism-related genes and baseline gene expression profiles using whole blood mRNA with long-term changes in growth while on r-hGH therapy. The objective of this study was to identify genetic markers and gene expression profiles associated with growth response (cm) 1 year after the initiation of r-hGH therapy in treatment-naïve prepubertal children with GHD or TS. This study demonstrates that a broad range of genes, related in particular to cell signaling, are associated with growth response to r-hGH. It also shows that the associated genes differ between GHD and TS, and that these genetic markers and expression profiles are associated with high or low first-year growth responses to r-hGH in children with GHD or TS. This work indicates that pharmacogenomics could be used to predict a key outcome of r-hGH treatment.
Subjects and methods
This open-label, prospective study involved three steps. First, candidate genes involved in growth and metabolism were identified by a literature search and selected for inclusion based on advice from a board of growth experts (see online Supplementary Table 1, see section on supplementary data given at the end of this article for a list of the candidate genes). Then, individual genotypes were assessed for their effect on growth (using full genotype, as well as dominant and recessive models for carriers of major and minor alleles), and associated markers were identified. Finally, the predictive potential of these markers was evaluated by categorizing the patient population into three groups based on height change in three age bands (<8, 8–12 and >12 years): high (>75th percentile (≥Q3)), intermediate (between the 25th and 75th percentiles (>Q1–<Q3)) and low (<25th percentile (≤Q1)). Analysis was carried out separately for patients with GHD and TS.
This study was conducted in compliance with ethical principles based on the Declaration of Helsinki, the International Conference on Harmonization Tripartite Guideline for Good Clinical Practice, and all applicable regulatory requirements.
Patients and treatment interventions
In total, 170 patients (110 with GHD and 60 with TS) underwent a genetic analysis from a per-protocol population at 1 year of 182 patients (115 with GHD and 67 with TS). The patients were recruited in 14 countries from across the world (listed under the Acknowledgements section). All the patients were prepubertal at the start of treatment. The diagnosis of GHD was based on two different stimulation tests with a peak GH value <10 μg/l, using assays in the local center. Patients selected for r-hGH treatment were based on criteria used in the local units. Patients with GHD associated with etiologies such as CNS tumors with or without cranial irradiation were excluded. The median peak GH value was 4.1 μg/l (Table 1), and <25% of the patients had a value >5.6 μg/l, and only eight patients had a peak GH value between 7 and 10 μg/l. TS required karyotype confirmation. Patients with GHD received r-hGH at an average dose of 0.035 mg/kg per day, and patients with TS received an average dose of 0.051 mg/kg per day. Other hormone deficiencies (cortisol and thyroxine), if present, were appropriately treated. Compliance was monitored by recall in the last month of the study, and was estimated at an average of ∼90% in both conditions.
Patient demographic data at baseline. Data are number (%) or median (Q1 and Q3). Minimum and maximum values are shown in brackets.
|Per-protocol population at year 1||GHD (n=115)||Min, max values||TS (n=67)||Min, max values|
|Male (%)||69 (60)a||0 (0)|
|Female (%)||46 (40)a||67 (100)a|
|Age (years)||9.8 (6.8, 11.3)||2, 15||9.1 (6.3, 11.8)||3, 16|
|Mid-parental height SDS||−0.8 (−1.6, −0.1)||−4, +2||−0.1 (−0.9, 0.6)||−4, +2|
|Height SDS||−2.1 (−2.7, −1.7)||−6.5, −0.3||−2.4 (−3.1, −1.5)||−5.4, −0.2|
|BMI SDS||−0.3 (−1.0, +0.5)||−3, +10.3||+0.6 (−0.3, +1.6)||−2.2, +4.8|
|GH peak response (μg/l)||4.1 (2.6, 5.6)||0, 9||NA|
|IGF1 SDS||−1.8 (−2.8, −0.9)||−7.7, +1.1||−1.2 (−2.1, −0.5)||−4.5, +1.7|
|IGFBP3 SDS||−0.2 (−1.1, +0.5)||−5.3, +2.2||+0.3 (−0.2, +0.7)||−2.3, +2.1|
GHD, GH deficiency; IGFBP3, insulin-like growth factor binding protein 3; NA, not applicable; Q, quartile; TS, Turner syndrome.
All were Tanner stage 1 at baseline. Thirty-seven children with GHD and 12 girls with TS entered puberty over the first year. DNA samples for genotyping were available for 110 patients with GHD and 60 girls with TS.
Growth parameters were converted to SDS using the Sempé reference data (16), so that all children were compared with the same standard. Baseline insulin-like growth factor 1 (IGF1) and IGF binding protein 3 (IGFBP3) were measured in a central laboratory (qLAB, Livingston, Edinburgh, UK), using the DPC chemiluminescent immunoassay (Immunolite 2000; Siemens Healthcare Diagnostics, Norwood, MA, USA). Levels were converted to SDS using relevant reference data (17). Baseline characteristics are shown in Table 1.
Genotyping was performed centrally on DNA extracted from whole blood using an Illumina GoldenGate micro array, containing 1536 single nucleotide polymorphisms (SNPs) located in 103 candidate genes related to i) the GH/IGF1 axis, ii) bone and cell growth and iii) glucose and lipid metabolisms. A total of 1451 SNPs were successfully genotyped. Prior to analysis, the genotyping data for these SNPs were filtered to remove SNPs with low minor allele frequency (<10%), those with a call rate below 95%, and those (except for X-linked SNPs in girls with TS and boys with GHD) showing significant deviation from the Hardy–Weinberg equilibrium using a Bonferroni correction for 1451 tests. After this cleaning step, 1182 SNPs in patients with GHD and 1183 SNPs in patients with TS remained for analysis. All analyses were performed centrally by the Bioinformatics Group at Merck Serono.
Gene expression profiling was carried out on whole blood RNA extracted centrally by qLAB using the PAXgene 96 blood RNA Kit (Qiagen) at baseline: 67 samples were available for GHD and 44 for TS. Reduction of globin mRNA was undertaken using the Ambion GLOBIN clear Human Kit (Life Technologies). The quality of RNA was assessed using an ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA) and qualified using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). cRNA was generated using the Two-Cycle Eukaryotic Target Labeling Kit (Affymetrix, Santa Clara, CA, USA) and a final quality check was performed before hybridization to Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays. Arrays were then scanned on an Affymetrix GeneChip 3000 7G scanner and assessed for quality against internal and hybridization controls. All analyses were performed centrally by the Bioinformatics Group at Merck Serono.
Processing and normalization of the raw gene expression data were performed on GHD and TS samples using a Robust Multi-array Average background correction modified for probe sequence with quantile normalization and median polish (Partek Genomics Suite version 6.3, Partek Inc., St. Louis, MO, USA). Outliers were identified by cross-validation using principal component analysis (PCA) and Isomap multidimensional scaling (Qlucore Omics Explorer 2.2, Qlucore AB, Lund, Sweden) to generate first-year growth response datasets in GHD and TS. A variance cut-off relative to the variable with the largest variance (σmax) was used to remove noninformative probes; this was set at 0.05 σ/σmax (Qlucore Omics Explorer 2.2). All processing of array data was performed at the University of Manchester.
SNPs associated with first-year growth were identified using the Kruskal–Wallis rank sum test on the genotype (additive model), the presence or the absence of the major allele (dominant model) and the presence or the absence of the minor allele (recessive model). For nonpseudoautosomal X-linked markers, boys with GHD were analyzed separately from girls with GHD. As a candidate gene, rather than a whole genome, approach was being used, both unadjusted P values and adjusted P values calculated using a Bonferroni correction that takes into account the number of linkage disequilibrium (LD) blocks present in the gene containing the SNP are reported for each SNP.
Markers were then tested in a second stage of the analysis, where patients were classified by quartiles, based on the normal distribution of growth response, as high (≥Q3), intermediate (>Q1–<Q3) or low responders (≤Q1) in each of three age groups (<8, 8–12 and >12 years) to control for the potential impact of age on response to r-hGH. Markers were assessed by comparing high responders vs intermediate+low responders, and low responders vs intermediate+high responders. All P values were calculated using Fisher's exact test and are shown as both unadjusted and Bonferroni-corrected values using the number of LD blocks within each candidate gene.
All demographic and growth data were analyzed by the Biostatistics Group at Merck Serono. Both the continuous and categorical analyses were conducted by Genizon BioSciences (Montreal, QC, Canada).
Country of origin analysis
In order to address whether country of origin or population stratification may be a confounding factor in response to r-hGH, a PCA was undertaken using the PLINK genetic analysis software (http://pngu.mgh.harvard.edu/∼purcell/plink/) by PGx Services. The genotypes for the 1182 GHD and 1183 TS SNPs were first screened to produce Tag SNPs that were in linkage equilibrium (R2<0.2 for LD between any two Tag SNPs). This was performed twice, independently, to generate lists of Tag SNPs for GHD and TS, on which PCA was carried out. The first two PCs were then used to assess impact on growth response.
Gene expression profiles
Gene expression associated with first-year growth response (cm) in GHD and TS was identified in low vs intermediate+high responders, and in high vs intermediate+low responders (as defined above) using ANOVA (P<0.05), with control for gender and age. Control for age was undertaken as we have recently shown that gene expression in healthy children is age dependent (18). In order to better understand the function and significance of these growth-associated genes, the analysis of inferred protein–protein interaction networks was performed using Ingenuity Pathways Analysis (IPA) Software. This allows differentially expressed genes to be correlated with biologic pathways. IPA was also used to generate inferred interaction networks derived from the genes associated with growth response. Gene expression data were then mapped onto these inferred networks to allow the integration of gene expression and genetic analyses, and to assess the presence of putative expression quantitative trait loci (eQTL). All analyses of array data were performed at the University of Manchester.
In silico evaluation of predicted function for significant SNPs
The predicted consequences of an SNP on transcriptional activity have been derived based on data from many different cell lines in which transcription factors and their binding sites responsible for modulating gene transcription, as identified by chromatin immunoprecipitation sequencing (ChIP-seq), are listed in the Encyclopaedia of DNA Elements (ENCODE) database (http://genome.ucsc.edu/ENCODE/) (19). Using this database, SNPs associated with growth response to r-hGH in this study, which lie in or near these binding sites and have been shown to have an impact on transcription, were identified.
Genetic markers and expression profiles associated with height change in children with GHD
The children with GHD had a median basal growth rate of 4 (Q1, 3; Q3, 6) cm/year, and then grew a median of 8.5 (Q1, 7.3; Q3, 10.2) cm over the first year. Ten polymorphisms within seven different genes were found to be significantly associated with this growth response, assessed as a continuous trait (Table 2). These included the gene coding for the major GH-dependent carrier of IGF1 in the circulation, IGFBP3; signaling molecules GRB10 and SOS1 (MAPK pathway); the phosphatase INPPL1; the growth factor TGFα the tumor suppressor TP53; and CYP19A1, a P450 cytochrome enzyme with aromatase activity. For each polymorphism, the difference in growth between alleles or genotypes was >1 cm over the first year, representing ∼20% of first-year increment in growth.
Single nucleotide polymorphisms (SNPs) in genes associated with first-year growth response in (A) GHD and (B) TS. Mean height change for genotypes is shown. More than one SNP was associated with growth for IGFBP3, GRB10, TGFα and INPPL1.
|Gene||Function||SNP ID||Model||Genotype (n)||Mean height change, cm (s.d.)||Nonadjusted P value||Adjusted P value|
|GRB10||Insulin and IGF1 signaling||rs1024531||Genotype||GG (5)||6.2 (1.4)||0.0005||0.01|
|GA (45)||8.0 (2.0)|
|AA (60)||9.4 (1.9)|
|rs1024531||Allelea||AA (60)||9.4 (1.9)||0.0006||0.0121|
|GG and GA (50)||7.9 (2.0)|
|rs12536500||Allelea||CC (70)||9.2 (2.0)||0.001||0.0253|
|TT and TC (40)||7.9 (2.0)|
|rs933360||Allelea||TT (71)||9.2 (2.2)||0.002||0.0448|
|TC and CC (39)||8.0 (1.6)|
|IGFBP3||Binding protein for IGFs||rs3110697||Alleleb||AA (18)||7.5 (2.0)||0.002||0.0117|
|GG and GA (91)||9.0 (2.1)|
|rs10255707||Alleleb||CC and CT (92)||9.0 (2.1)||0.006||0.0278|
|TT (13)||7.3 (2.0)|
|rs3110697||Genotype||AA (18)||7.4 (2.0)||0.009||0.0442|
|AG (42)||9.2 (2.1)|
|GG (49)||8.9 (2.0)|
|TGFα||Growth factor||rs958686||Genotype||GG (14)||7.4 (1.0)||0.002||0.0351|
|GC (60)||8.6 (2.1)|
|CC (36)||9.6 (2.3)|
|rs958686||Allelea||CC (36)||9.6 (2.3)||0.002||0.046|
|GG and GC (74)||8.0 (2.0)|
|CYP19A1||Aromatase enzyme for estrogen synthesis||rs10459592||Allelea||GG (29)||10 (2.2)||0.003||0.043|
|TT and TG (81)||8 (1.9)|
|SOS1||MAPK signaling pathway||rs2888586||Allelea||CC (33)||7.8 (1.8)||0.0095||0.0476|
|TT and CC (77)||9.0 (2.0)|
|TP53||Cell cycle regulation||rs2909430||Allelea||TT (77)||9.1 (2.1)||0.014||0.0414|
|TC and CC (33)||8.0 (1.8)|
|INPPL1||Regulation of insulin and growth factor receptor signaling||rs2276048||Allelea||AA (72)||8.4 (1.9)||0.0254||0.0254|
|AG and GG (38)||9.5 (2.3)|
|rs2276048||Genotype||AA (72)||8.4 (1.9)||0.0497||0.0497|
|AG (34)||9.4 (2.4)|
|GG (4)||10.1 (1.3)|
|LHX4||Pituitary transcription factor||rs3845395||Allelea||GG (31)||6.9 (1.4)||0.002||0.0485|
|GC and CC (29)||8.3 (1.8)|
|KRAS||MAPK signaling pathway||rs12579073||Genotype||AA (22)||8.0 (1.7)||0.008||0.0461|
|AC (24)||6.8 (1.4)|
|CC (14)||8.4 (1.9)|
Allele, major allele recessive.
Allele, major allele dominant.
To control for the potential impact of age on growth response, genes associated with growth, defined as high (≥Q3), intermediate (>Q1–<Q3) or low responders (≤Q1) in each of three age groups, were identified. Four of the genes in the continuous trait analysis were also found by this categorical analysis (Table 3), while a further four genes were added: IGFII (IGF2), CYR61 (a secreted protein, also known as IGFBP10), AKT1 (a signaling molecule activated by PI3K) and SOS2 (MAPK signaling). Importantly, the r-hGH doses between the high, intermediate and low responders did not differ (Table 4). To control for the potential impact of country of origin on response, a PCA was undertaken. The first principal component (PC) based on the Tag SNPs clearly separated those children from Asia from all other children (Fig. 1A). However, there was complete overlap in growth response between the groups (Fig. 1B).
Genes identified using the categorical model, based on quartiles (Q) of growth response and age bands of (A) patients with GHD and (B) girls with TS.
|Gene||Function||Marker||Categorical model||Categorical nonadjustedP value||Categorical adjustedP value||Relative risk||95% CI relative risk||Category 1||Category 2||Genotype marker for category 1||Genotype marker for category 2|
|GRB10||Insulin and IGF1 signaling||rs1014384||Dominant||0.0012||0.0245||3.6||2.15, 5.94||L||I + H||GG||AA and AG|
|GRB10a||Insulin and IGF1 signaling||rs933360||Recessive||0.0012||0.0259||4.8||1.54, 14.73||H||I + L||TT||CC and TC|
|GRB10||Insulin and IGF1 signaling||rs4521715||Recessive||0.0013||0.0266||4.6||1.48, 14.14||H||I + L||AA||GG and AG|
|CYP19A1a||Aromatase enzyme||rs10459592||Recessive||0.0030||0.0455||2.6||1.44, 4.71||H||I + L||GG||TT and TG|
|SOS2||MAPK signaling||rs13379306||Recessive||0.0060||0.0482||2.4||1.31, 4.49||L||I + H||AA and AC||CC|
|CYR61||Secreted protein, IGFBP10||rs9658584||Recessive||0.0083||0.0167||2.7||1.26, 5.80||H||I + L||GG||CC and CG|
|SOS1a||MAPK signaling||rs2888586||Recessive||0.0086||0.0429||3.7||1.21, 11.42||H||I + L||TT and TC||CC|
|IGF2||Growth factor||rs3213221||Dominant||0.0138||0.0414||2.5||1.36, 4.45||H||I + L||CC||GG and CG|
|AKT1||Activated by PI3K||rs1130214||Recessive||0.0290||0.0290||2.3||1.10, 4.68||L||I + H||AA and AC||CC|
|INPPL1a||Regulation of insulin and growth factor signaling||rs2276048||Recessive||0.0392||0.0392||2.0||1.10, 3.75||H||I + L||GG and AG||AA|
|LHX4a||Transcription factor||rs3845395||Recessive||0.0003||0.0067||7.5||1.86, 30.11||H||I + L||CC and GC||GG|
|LHX4||Transcription factor||rs4652492||Recessive||0.0013||0.0275||NA||NA||H||I + L||AA and AG||GG|
|PTPN1||Protein tyrosine phosphatase (in insulin and JAK2 signaling)||rs13041704||Dominant||0.0037||0.0261||4.7||2.83, 7.71||L||I + H||CC||AA and AC|
|PIK3R3||Regulatory subunit of PI3K||rs809775||Recessive||0.006||0.0181||3.3||1.51, 7.14||L||I + H||TT||AA and AT|
|PPP1CB||Catalytic subunit of protein phosphatase 1||rs6725177||Recessive||0.006||0.0299||3.3||1.41, 7.86||L||I + H||CC||GG and GC|
|CDK4||Cell cycle regulator||rs2069502||Recessive||0.0073||0.0146||5.0||1.25, 20.07||H||I + L||TT and TC||CC|
|SOS1||MAPK signaling||rs2168043||Recessive||0.0079||0.0394||3.3||1.44, 7.33||H||I + L||AA and AC||CC|
|IGFBP3||IGF binding protein||rs3110697||Recessive||0.0084||0.0421||3.3||1.31, 8.30||L||I + H||GG||AA and AG|
|TGFB1||Growth factor||rs4803455||Recessive||0.0126||0.0379||NA||NA||H||I + L||AA and AC||CC|
|MYOD1||Transcription factor (in muscle)||rs3911833||Recessive||0.0476||0.0476||5.2||0.74, 36.47||L||I + H||CC||TT and TC|
GHD, GH deficiency; H, high responder (≥Q3); I, intermediate responder (>Q1, <Q3); L, low responder (≤Q1); NA, not applicable; Q, quartile; TS, Turner syndrome.
Genes also identified in the continuous analysis.
Mean r-hGH doses in GHD and TS in those with high (≥Q3), intermediate (>Q1, <Q3) or low responses (≤Q1).
|Mean r-hGH dose (μg/kg per day)||0.0341||0.0350||0.0335|
|Minimum, maximum values||0.0243, 0.0524||0.0164, 0.0563||0.0218, 0.0621|
|Mean r-hGH dose (μg/kg per day)||0.0469||0.0482||0.0490|
|Minimum, maximum values||0.0416, 0.0563||0.0375, 0.0607||0.0347, 0.0581|
GHD, GH deficiency; r-hGH, recombinant human GH; Q, quartile; TS, Turner syndrome.
A total of 1886 gene expression probe sets corresponding to 1188 genes (Ingenuity Knowledge Base) were associated with first-year growth in the expression profiles for the low responder analysis (Fig. 2A): a distinct pattern of gene expression at baseline in the low responders compared with the other profiles was identified. A total of 1127 gene expression probe sets corresponding to 865 genes (Ingenuity Knowledge Base) were associated with the high responder analysis with the expression profile in the high responders differing from the rest (data not shown). Network analysis of the human interactome associated with these genes indicated that glucocorticoid, estrogen and insulin receptor signaling, and protein ubiquitination pathways were represented as top canonical pathways (P<0.001).
Genetic markers associated with height change in girls with TS
Girls with TS had a median basal growth rate of 4 (Q1, 2; Q3, 6) cm/year, and then grew a median of 7.2 (Q1, 6.1; Q3, 9.1) cm over the first year. Two polymorphisms within two genes were found to be significantly associated with this growth response, assessed as a continuous trait (Table 2). These included the signaling molecule KRAS (MAPK pathway) and the pituitary transcription factor LHX4. As seen for GHD, the difference in growth between different alleles or genotypes was >1 cm over the first year.
LHX4, identified in the continuous trait analysis, was also found in the categorical analysis. In contrast to GHD, a further eight genes were added (Table 3): IGFBP3 and SOS1 (MAPK signaling), both found in GHD; PIK3R3, PTPN1 and PPP1CB (all modulators of signaling); CDK4 (a cell cycle regulator); TGFB1 (a growth factor); and MYOD1 (a muscle transcription factor). Importantly, the r-hGH doses between the high, intermediate and low responders did not differ (Table 4). Similar to GHD, the first PC based on the Tag SNPs separated those children from Asia from all other children, with the exception of one child (Fig. 1C). However, there was complete overlap in growth response between the groups (Fig. 1D).
A total of 1003 gene expression probe sets corresponding to 673 genes (Ingenuity Knowledge Base) were associated with first-year growth in the expression profiles for the low responder analysis (Fig. 2B): a distinct pattern of gene expression at baseline in the low responders compared with the other profiles was identified. A total of 700 gene expression probe sets corresponding to 506 genes (Ingenuity Knowledge Base) were associated with the high responder analysis with the expression profile in the high responders differing from the rest (data not shown). In contrast to GHD, no growth factor-related canonical pathways were represented by these genes.
Integration of genetic and gene expression data
To integrate the gene expression data with the genetic analysis, inferred networks were generated from the genetic data using the IPA functional association algorithm. In children with GHD, this procedure generated a network from all the associated genes (AKT1, CYP19A1, CYR61, GRB10, IGF2, IGFBP3, INPPL1, SOS1, SOS2 and TGFα with the exception of TP53; Fig. 3A). In children with TS, an inferred network was generated from all the associated genes (CDK4, IGFBP3, KRAS, MYOD1, PIK3R3, PTPN1 and SOS1 with the exception of LHX4 and PPP1CB; Fig. 3B). Gene expression data associated with first-year growth were mapped onto the inferred networks (Fig. 3A and B). One putative eQTL (a gene with both a genetic association and a change in expression) was identified in GHD, AKT1, and two putative eQTLs were identified in TS, KRAS and MYOD1. Other inferred network genes were also associated with changes in gene expression in either or both low and high quartiles of first-year growth (Fig. 3A and B), thus implying functional changes correlated with the genetic associations.
In silico prediction of functional consequences of SNPs
Using the ENCODE database, in which transcription factor binding has been assessed in multiple cell lines by ChIP-seq, the SNPs in IGFBP3, GRB10, CYP19A1 and LHX4 fall within, or close to, transcription binding sites (Table 5).
Physical association of significant SNPs in continuous and categorical analyses in (A) GHD and (B) TS to known transcription factor binding sites.
|Gene||SNP||Transcription factor binding sitesa|
|GRB10||rs1024531||Within 200 bp of ‘Neurone-restrictive Silencer factor’ (NRSF) site|
|rs12536500||Within 200 bp of ‘Upstream Regulatory factor’ (USF) half site|
|CYP19A1||rs10459592||Within Fos/Jun site|
|IGFBP3||rs3110697b||Within 200 bp of STAT3 and EGR1 sites|
|rs10255707||Within EGR1 site|
|CYR61||rs9658584||Within P300/JUN/KAP1 sites|
|AKT1||rs1130214||Within CTCF/Rad21 sites|
|LHX4||rs3845395||Within 200 bp of CTCF site|
|rs4652492||Within 200 bp of CTCF/Rad21 sites|
|PIK3R3||rs809775||Within 200 bp of STAT3 site|
|CDK4||rs2069502||Within 200 bp of CTCF site|
|SOS1||rs2168043||Within CEBPB site|
|IGFBP3||rs3110697b||Within 200 bp of STAT3 and EGR1 sites|
Bp, base pairs; GHD, GH deficiency; SNP, single nucleotide polymorphism; TS, Turner syndrome.
These data have been derived from many different cell lines of which transcription factors and their binding sites responsible for modulating gene transcription, as identified by ChIP-seq, are listed in the ENCODE database (http://genome.ucsc.edu/ENCODE/). The SNPs identified in this study lie in or near these binding sites.
Same SNP found in both GHD and TS.
GH is widely used to treat a range of growth disorders. Children who are sensitive to r-hGH in the first year of treatment and grow well are more likely to continue to gain height in the long-term (20, 21, 22). Identification of those who will be either sensitive or, more importantly, insensitive to r-hGH has important implications for counseling and clinical management. Current models to predict growth response to r-hGH over the first years of treatment have been based primarily on baseline auxologic characteristics and r-hGH dose, the latter being the only predictor that the treating physician can modulate (20, 21, 22); some models also include baseline IGF1 and IGFBP3 levels (both being GH-dependent biomarkers) and short-term change in bone markers (23, 24). In GHD, models based on auxology can predict up to 65% of the variability in the first year, and with the addition of biochemical markers, this is increased to 85%. In non-GH-deficient conditions, such models predict no more than 40–52% of the variability in first-year response; these predictions often have low accuracy (22). The PREDICT study is the first long-term study to evaluate the extent to which a range of genetic markers are associated with growth response.
For the DNA studies, a candidate gene approach was adopted, picking genes that affect the growth process not only directly but also indirectly by affecting metabolic pathways. Two very different growth disorders were examined, namely GHD, in which the cause was undefined, and TS, in which there was absence or structural abnormality of one X chromosome. The majority of the SNPs associated with first-year response to r-hGH differed between these conditions, implying that the genetic influences on the action of exogenous GH are not the same in the two conditions. In addition, this difference may relate to a ‘replacement’ GH dose in GHD vs a ‘pharmacologic’ dose in TS. However, SNPs in two genes, IGFBP3 and SOS1, were common to both conditions, and these genes may have an impact on r-hGH sensitivity independent of the etiology of the growth disorder. Importantly, the differences in growth associated with the SNPs shown in Table 2 are of sufficient magnitude to be clinically important, accounting for ∼20% of the first-year response in this study.
Short stature associated with GHD without a defined etiology covers a broad spectrum, ranging from those with severe GHD, low IGF1 levels and very poor growth performance through to those with a mild impairment of GH secretion and low–normal IGF1, who in the majority of cases re-test as GH sufficient in late adolescence. This is the range of children who are treated as GHD, and if pharmacogenomics is going to aid the management of such children, then the genes associated with growth response to r-hGH must be significant across this broad diagnostic range. The PREDICT GHD cohort reflects this range of deficiency within the GH–IGF axis; children with severe GHD are represented, but also children with a modest impairment of GH secretion with normal IGF1 and IGFBP3 serum levels. It is also important to control for other confounding factors including age, r-hGH dose, pubertal progress, compliance and ethnic background. Therefore, we stratified the patients by age for the categorical analysis, using three age groups, each associated with quartiles of response. This identified some additional genes that were associated with growth response, more so in TS than GHD (Table 3). In the first month of this study, the dose of r-hGH to be given to children with GHD and TS was specified; thereafter, the clinicians determined the dose most appropriate for their patient. It was reassuring to find that the dose of r-hGH in both conditions was the same across the quartiles of growth response (Table 4), indicating that the dose was unlikely to be a major confounding factor. All were prepubertal at baseline, with approximately one-third entering the first stages of puberty by the end of the first year. This may have impacted modestly on growth rate in girls but not in boys. Compliance, as assessed by recall of injections given over the last month, was high in both conditions (mean ∼90%). It is very difficult to know the reliability of these data, and it is likely that this is a significant overestimation of compliance. It is well recognized that SNP frequencies vary between ethnicities, and this proved to be the case in this study with children from countries in South Asia separating very clearly from children from all other countries in the study when applying PCA to Tag SNPs (Fig. 1A and C). Nevertheless, this did not influence the magnitude of response to r-hGH between these two groups (Fig. 1B and D).
We also used a whole genome approach by analyzing gene expression profiles at baseline, using whole blood mRNA; the use of a PBMC model for variation of gene expression in response to r-hGH has previously been validated (11, 12). Gene expression signatures associated with both low and high growth responses in GHD and TS have been defined. In this study, genes related to growth factor action, signal transduction and cell cycle regulation were identified, emphasizing that many cellular processes affect response to r-hGH. In order to examine the potential functionality of the SNPs, we have looked at their proximity to transcription factor binding sites (Table 5). One of the IGFBP3 SNPs (rs10255707) is located within an early growth response 1 (EGR1) binding site. EGR1 is a zinc-finger, nuclear protein that functions as a regulator of transcription, with studies suggesting that it is a cancer suppressor gene (gene ID: http://www.ncbi.nlm.nih.gov/gene/1958).
The principal carrier protein for IGF1, IGFBP3, whose expression is GH-dependent, was identified in both conditions (Tables 2 and 3B). IGF1 SNPs were not identified. This implies that IGFBP3 could have a greater overall impact on the variability of growth responses to r-hGH than IGF1. At the cellular level, IGFBP3 has both IGF1-dependent and direct, IGF1-independent effects on cell growth regulation (25). For the rs3110697 IGFBP3 SNP, which is within 200 bp of STAT3 and EGR1 binding sites on the IGFBP3 gene (Table 5), carriage of the G allele in GHD was associated with a high growth response (Table 2), but in girls with TS, carriage of the GG genotype was associated with a low growth response (Table 3B). These genotypes have been shown to associate with different serum levels of IGFBP3 in an adult multi-ethnic cohort (26); lowest levels were reported in those carrying the AA genotype, and 17% higher levels were found in those with a GG genotype. Thus, in GHD, a low growth response would associate with a relatively low IGFBP3 serum level, while in TS, a higher growth response would associate with low IGFBP3 levels. These apparently conflicting data are, however, supported by other clinical data; in a study assessing parameters that determine growth response on r-hGH treatment in GHD, IGFBP3 SDS was shown to have a positive relationship with change in height SDS (27). In a pharmacogenomic study examining the impact of an IGFBP3 SNP that also affects serum IGFBP3 in GHD, genotypes associated with higher IGFBP3 levels were associated with greater growth responses (28). In contrast, IGFBP3 has been identified as a negative factor in prediction models for response to r-hGH in children who are small for gestational age (23). In addition, in an ex vivo fibroblast model of growth factor action, TS cells produced more IGFBP3 than control cells in the basal state, but generated less IGFBP3 in response to IGF1 stimulation, implying that higher IGFBP3 levels in the media around these cells were inhibiting IGF1 action (29). Therefore, the influence of IGFBP3 appears to be disease dependent, and this is reflected in the divergent growth responses associated with the same IGFBP3 SNP in GHD and TS. These differing associations may be due to the different r-hGH doses received by patients with GHD and TS (larger in TS), as well as differences in growth plate resistance to GH and/or IGF1.
In patients with GHD, six SNPs in GRB10 were associated with growth response (Tables 2 and 3A). GRB10 interacts with insulin and IGF1 receptors; its overexpression inhibits tyrosine kinase receptors leading to growth suppression (gene ID: http://www.ncbi.nlm.nih.gov/gene/2887). Two of the SNPs are within 200 bp of transcription factor binding sites and would be predicted to have an effect on transcriptional regulation (Table 5). The SNP in the CYP19A1 gene is located within a Fos–Jun site and has been shown to impact transcriptional activity – the C allele had 60% higher promoter activity than the A allele (30). Growth rate in GHD was lower in TT homozygotes, implying that lower aromatase activity would associate with poorer growth responses. This observation suggests that even before puberty, low levels of estrogen may contribute to growth response to r-hGH.
In girls with TS, the transcription factor LHX4, which when mutated is associated with multiple pituitary hormone deficiencies, was associated with growth response. Girls with TS have normal endogenous GH secretory capacity. However, this SNP is located within 200 bp of a CTCF-binding site; CTCF is another zinc-finger protein known to regulate transcription (Table 5). This association may suggest a role for regulation of pituitary hormones in first-year response to r-hGH treatment in TS. In addition to IGFBP3, SNPs identified in both conditions included genes within the MAPK pathway – SOS1 and SOS2 in GHD, and SOS1 and KRAS in TS. SOS1 and KRAS, but not SOS2, have been implicated in human rasopathies, including mutations in SOS1 and KRAS in Noonan syndrome and KRAS mutations in cardiofaciocutaneous syndrome (31). This indicates that the MAPK pathway is a key regulator of r-hGH responsiveness.
Using a network approach to analysis, we have shown that genes within networks associated with growth response are differentially expressed between high and low responders to r-hGH in both TS and GHD (Fig. 3). Importantly, the latter included three genes containing SNPs associated with growth response (one in GHD, two in TS), demonstrating that these SNPs are associated with a change in expression in that gene.
This study has identified potential genetic markers and expression profiles for growth response to r-hGH in patients with GHD or TS, and has broadened considerably the spectrum of genes associated with GH action. These findings must be validated in independent cohorts, including the full range of growth disorders treated with r-hGH. These results indicate that pharmacogenomics could have a role to play in a personalized strategy for managing r-hGH treatment in children.
This is linked to the online version of the paper at http://dx.doi.org/10.1530/EJE-13-0069.
Declaration of interest
P Clayton and P Chatelain have received research support and honoraria as speakers and consultants from Merck Serono S.A. (Geneva, Switzerland). A Stevens has received honoraria as a speaker from Merck Serono S.A. L Tato has received research support and honoraria as a speaker from Merck Serono S.A. H W Yoo has received honoraria from Merck Serono S.A. C Deal has received research support and honoraria as a speaker, clinical investigator and consultant from EMD Serono, Inc. (Canada) and/or Merck Serono S.A. G R Ambler, P Croteau and A Belgorosky have nothing to disclose. J Raelson has received consultancy honoraria from Merck Serono. C Olivier is a former employee of Merck Serono S.A. and B Destenaves is an employee of Merck Serono S.A. S Quinteiro has received honoraria as a speaker and consultant for Merck Serono S.A.
The genetic analysis performed by J Raelson and P Croteau (Genizon Biosciences) was funded by a branch of Merck Serono S.A. (Coinsins, Switzerland), an affiliate of Merck KGaA (Darmstadt, Germany).
This work was supported by Merck Serono S.A., Switzerland.
We thank Valentina Peterkova (Russian Academy of Medical Sciences, Institute of Clinical Endocrinology, Moscow) for her participation in the study and contribution to earlier versions of this manuscript. We are very grateful to all the ‘PREDICT’ investigators for their contributions to this study. The genetic analyses were supervised by J Wojcik, Director of Bioinformatics at Merck Serono. We thank T Theocharis, Biostatistics at Merck Serono, for his contribution to analysis of the growth data. The first draft and subsequent edits of this manuscript were written by P Clayton. Editorial assistance was provided by Nadia Hashash, PhD, Medicus International and MaiLee Wong, PhD, Caudex Medical (funded by Merck Serono). The analysis of the array data was undertaken at the University of Manchester by A Stevens, and this work was facilitated by the Manchester Biomedical Research Centre. PREDICT investigators: Argentina: A Belgorosky (Buenos Aires). Australia: G Ambler (Westmead). Austria: K Kapelari (Innsbruck). Canada: C Deal (Montreal); J Hamilton (Toronto). Finland: J Jääskeläinen (Kuopio). France: Y Brusquet (Puyricard); S Cabrol (Paris); P Chatelain (Lyon); M Colle (Bordeaux); R Coutant (Angers); Y Le Bouc (Paris); R Reynaud (Marseille); J-P Salles (Toulouse) and J Weill (Lille). Germany: R Pfäffle (Leipzig); M Ranke and G Binder (Tübingen). Italy: M Bozzola (Pavia); F Buzi (Brescia); M Cappa (Rome); A Cicognani (Bologna); M Maghnie (Genova); L Tato and F Antoniazzi (Verona). Norway: E Vangsøy Hansen (Bergen) and D Veimo (Bodø). Russia: E Bashnina (St Petersburg); V Peterkova (Moscow); J Skorodok (St Petersburg); L Sultanova (Kazan). Spain: A Carrascosa (Barcelona); A Ferrandez Longas (Zaragoza); R Gracia Bouthellier (Madrid); J P Lopez Siguero (Malaga); S Quinteiro (Las Palmas de Gran Canaria); M D Rodriguez-Arnao (Madrid); A Rodriguez Sanchez (Madrid). South Korea: D H Kim (Seoul); S W Yang (Seoul) and H W Yoo (Seoul). Sweden: J Dahlgren (Göteborg) and L Hagenäs (Stockholm). Taiwan: J W Hou (Taipei) and T J Wang (Kaohsiung County). UK: P Clayton (Manchester) and C Kelnar (Edinburgh).
HoKK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. European Journal of Endocrinology2007157695–700. (doi:10.1530/EJE-07-0631).
GoetghebeurMMWagnerMKhouryHRindressDGregoireJPDealC. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients. Cost Effectiveness and Resource Allocation201084. (doi:10.1186/1478-7547-8-4).
LanktreeMBGuoYMurtazaMGlessnerJTBaileySDOnland-MoretNCLettreGOngenHRajagopalanRJohnsonT. Meta-analysis of dense genecentric association studies reveals common and uncommon variants associated with height. American Journal of Human Genetics2011886–18. (doi:10.1016/j.ajhg.2010.11.007).
RenehanAGSolomonMZwahlenMMorjariaRWhatmoreAAudiLBinderGBlumWBougneresPSantosCD. Growth hormone receptor polymorphism and growth hormone therapy response in children: a Bayesian meta-analysis. American Journal of Epidemiology2012175867–877. (doi:10.1093/aje/kwr408).
WassenaarMJDekkersOMPereiraAMWitJMSmitJWBiermaszNRRomijnJA. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism2009943721–3730. (doi:10.1210/jc.2009-0425).
WhatmoreAJPatelLClaytonPE. A pilot study to evaluate gene expression profiles in peripheral blood mononuclear cells (PBMCs) from children with GH deficiency and Turner syndrome in response to GH treatment. Clinical Endocrinology200970429–434. (doi:10.1111/j.1365-2265.2008.03477.x).
ElmlingerMWKuhnelWWeberMMRankeMB. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clinical Chemistry and Laboratory Medicine200442654–664. (doi:10.1515/CCLM.2004.112).
RankeMBLindbergAChatelainPWiltonPCutfieldWAlbertsson-WiklandKPriceDA. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. Journal of Clinical Endocrinology and Metabolism1999841174–1183. (doi:10.1210/jc.84.4.1174).
RankeMBLindbergAChatelainPWiltonPCutfieldWAlbertsson-WiklandKPriceDA. Predicting the response to recombinant human growth hormone in Turner syndrome: KIGS models. KIGS International Board. Kabi International Growth Study. Acta Paediatrica. Supplement199988122–125. (doi:10.1111/j.1651-2227.1999.tb14420.x).
SchonauEWestermannFRauchFStabreyAWassmerGKellerEBramswigJBlumWF. A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency. European Journal of Endocrinology200114413–20. (doi:10.1530/eje.0.1440013).
ChengIDeLellisHKHaimanCAKolonelLNHendersonBEFreedmanMLLeML. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. Journal of Clinical Endocrinology and Metabolism2007923660–3666. (doi:10.1210/jc.2007-0790).
DasUWhatmoreAJKhosraviJWalesJKButlerGKibirigeMSDiamandiAJonesJPatelLHallCM. IGF-I and IGF-binding protein-3 measurements on filter paper blood spots in children and adolescents on GH treatment: use in monitoring and as markers of growth performance. European Journal of Endocrinology2003149179–185. (doi:10.1530/eje.0.1490179).
CostalongaEFAntoniniSRGuerraGJrColettaRRFrancaMMBrazAFMendoncaBBArnholdIJJorgeAA. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and −202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency. Pharmacogenomics Journal201212439–445. (doi:10.1038/tpj.2011.13).
(J Raelson is now at PGx-Services, Montréal, Quebec, Canada)
(P Croteau is now at Caprion Protomics, Inc., Montréal, Quebec, Canada)
(B Destenaves is now at AstraZeneca, Cheshire, UK)
(C Olivier is now at Shire HGT, Nyon, Switzerland)